Skip to main content
padlock icon - secure page this page is secure

Peptidergic Regulation of Pheochromocytoma

Buy Article:

$68.00 + tax (Refund Policy)



Pheochromocytoma contains and may synthesize a large number of peptides such as opioids (Leu-, Met-enkephalin), VIP, gastrin, calcitonin gene related peptide (CGRP), somatostatin, and adrenocorticotrophic hormone (ACTH). Also, circulating level of these peptides may be elevated.

Although the precise contribution of these peptides secretion to the clinical features are largely unknown, it can be suggested that specific endocrine system could be involved in ectopic hormone production by pheochromocytoma. Indeed, it has occasionally been reported that pheochromocytoma is associated with Cushing's syndrome resulting from excess ACTH production.

As there are already many excellent reviews of this area, the discussion that follows will mainly focus on our data, including 1.Opioids, 2.Adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP), 3.Natriuretic peptides (NPs), 4.Leptin, 5.Endothelin 6. Angiotensin II receptor, 8. Chromogranin A and Catestatin.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: adrenocorticotrophic; adrenomedullin; calcitonin gene related peptide; pheochromocytoma; somatostatin

Document Type: Review Article

Publication date: June 1, 2003

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more